BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Biopeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Biopeutics's drugs run\, from Cli
 nicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT00610051-618@assetmemo.bio
DTSTAMP:20261121T005835Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:alprostadil: Phase 3 readout est. (NCT00610051)
DESCRIPTION:alprostadil\, phase 3\, Heart Failure.\nStudy: ALP-1 Continuous
  Intravenous Infusion to Maintain Clinical Stability in Advanced Heart Fai
 lure\nEstimated primary completion: November 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/alprostadil#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT00610051
URL:https://assetmemo.bio/drug/alprostadil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
